We hypothesized that icotinib following adjuvant chemotherapy would be more effective in reducing the risk of disease recurrence than chemotherapy alone for resected EGFR-mutated NSCLC in the adjuvant setting. Here, EGFR is linked to non-small cell lung carcinoma.